Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT07073326

Effects of Normobaric Hypoxic Training in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Conditions: MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Normobaric Hypoxia

Sex: All
Ages: 18 Years – 65 Years
Healthy volunteers: No
Phase: NA
Enrollment: 16
Sponsor: University of Trieste

Location: University of Trieste - Exercise Physiology and Kinesiology Lab Trieste Trieste

Summary

Altitude training has been suggested to be of potential support to improve some chronic clinical conditions, especially metabolic conditions. Normobaric hypoxia represents a promising system to simulate altitude training, and its efficacy and safety have been suggested in different conditions, including diabetes, obesity and hypertension. Metabolic dysfunction-associated steatotic liver disease (MASLD) can characterized by metabolic alterations (including altered body composition, lipid and glycemic profile, etc.), and might benefit from aerobic training performed in simulated altitude training (i.e., normobaric hypoxia). Mild altitude training will be proposed (equal to about 2'500 m, 15% FiO2) and compared to a sham normobaric normoxia condition, during a 6-week 3 times per week 50-min aerobic training (walking) at 60-65% of maximum heart rate (HRmax). Cardiorespiratory fitness, body composition, and metabolic profile will be investigated.

Eligibility Criteria

Inclusion Criteria: * Being diagnosed with MASLD from at the least 3 years * BMI \> 26 kg/m2 * Being sedentary Exclusion Criteria: * Cardiovascular, respiratory, renal complications * Hypertension * COPD * Previous history of acute mountain sickness or altitude-associated symptoms * Females only: pregnancy or breastfeeding

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07073326). StuddyBuddy aggregates publicly available trial information.